nach oben

Osteoporosis International

Erschienen in:

03.07.2019 | Original Article

Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

verfasst von: A. Svedbom, P. Hadji, E. Hernlund, R. Thoren, E. McCloskey, R. Stad, B. Stollenwerk

Erschienen in: Osteoporosis International | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study estimated the cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries (EU5) using the IOF reference cost-effectiveness model. Pharmacological fracture prevention as prescribed in clinical practice was cost-saving (provided more QALYs at lower costs) compared to no treatment in each of the EU5.

Purpose

To estimate the real-world cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries by population size: France, Germany, Italy, Spain, and the United Kingdom (UK) (collectively EU5).

Materials and methods

We analyzed sales data on osteoporosis drugs in each of the EU5 to derive a hypothetical intervention that corresponds to the mix of osteoporosis medication prescribed in clinical practice. The costs for this treatment mix were obtained directly from the sales data, and the efficacy of the treatment mix was estimated by weighing the treatment-specific fracture risk reductions from a published meta-analysis. Subsequently, we estimated the cost-effectiveness using costs per quality adjusted life year (QALY) of the intervention compared to no treatment in each of the EU5 using the International Osteoporosis Foundation (IOF) reference cost-effectiveness model. The model population comprised postmenopausal women, mean age 72 years with established osteoporosis (T-score ≤ − 2.5) among whom 23.6% had a prevalent vertebral fracture. The model was populated with country-specific data from the literature.

Results

Pharmacological fracture prevention as prescribed in clinical practice was cost-saving (provided more QALYs at lower costs) compared to no treatment in each country. The findings were robust in scenario analyses.

Conclusions

Pharmacological fracture prevention as prescribed in clinical practice is cost-saving in each of the EU5. Because of the under-diagnosis and under-treatment of post-menopausal osteoporosis, from a health economic perspective, further cost-savings may be reached by expanding treatment to those at increased risk of fracture currently not receiving any treatment.

Odén A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010–2040. Osteoporos Int 26(9):2243–2248CrossRefPubMed

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentral

Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster J-Y, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507–1529CrossRefPubMedPubMedCentral

Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29(9):1926–1928CrossRefPubMed

Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res 31(8):1485–1487CrossRefPubMed

Laius O, Pisarev H, Maasalu K, Kõks S, Märtson A (2017) Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004–2015. Arch Osteoporos 12(1):48CrossRefPubMed

Van der Velde R, Wyers C, Teesselink E, Geusens P, van den Bergh JP, de Vries F, Cooper C, Harvey N, van Staa T (2017) Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone 94:50–55CrossRefPubMed

Järvinen TL, Sievänen H, Kannus P, Jokihaara J, Khan KM (2011) The true cost of pharmacological disease prevention. BMJ 342:d2175CrossRefPubMed

Hiligsmann M, Evers SM, Sedrine WB, Kanis JA, Ramaekers B, Reginster J-Y, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205–224CrossRefPubMed

10.

Si L, Winzenberg T, Palmer A (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25(1):51–60CrossRefPubMed

11.

Zethraeus N, Borgström F, Ström O, Kanis J, Jönsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18(1):9–23CrossRefPubMed

12.

Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982. https://doi.org/10.1007/s00198-010-1424-x CrossRefPubMed

13.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E (2014) Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone 59:105–113CrossRefPubMed

14.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11(5):485–497CrossRefPubMed

15.

Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed

16.

Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194CrossRefPubMed

17.

Kanis J, Johnell O, De Laet C, Johansson H, Odén A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382CrossRefPubMed

18.

Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739CrossRefPubMed

19.

Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120–127. https://doi.org/10.1007/PL00004173 CrossRefPubMed

20.

Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781–1793. https://doi.org/10.1007/s00198-006-0193-z CrossRefPubMed

21.

Singer B, McLauchlan G, Robinson C, Christie J (1998) Epidemiology of fractures in 15 000 adults: the influence of age and gender. J Bone Joint Surg (Br) 80(2):243–248CrossRef

22.

Piscitelli P, Tarantino U, Chitano G, Argentiero A, Neglia C, Agnello N, Saturnino L, Feola M, Celi M, Raho C (2011) Updated incidence rates of fragility fractures in Italy: extension study 2002–2008. Clinical cases in mineral and bone. metabolism 8(3):54

23.

Darbà J, Kaskens L, Vilela FS, Lothgren M (2015) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res 7:105–117. https://doi.org/10.2147/ceor.s78349 CrossRefPubMedPubMedCentral

24.

Briot K, Maravic M, Roux C (2015) Changes in number and incidence of hip fractures over 12 years in France. Bone 81:131–137CrossRefPubMed

25.

Bleibler F, Rapp K, Jaensch A, Becker C, König H-H (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res 14(1):284. https://doi.org/10.1186/1472-6963-14-284 CrossRefPubMedPubMedCentral

26.

Kanis J, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12(12):989–995CrossRefPubMed

27.

Kanis J, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674CrossRefPubMed

28.

Kanis J, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427CrossRefPubMed

29.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209–217CrossRefPubMed

30.

Excellence NIfC (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London

31.

Allen MR, Burr DB (2011) Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 49(1):56–65CrossRefPubMed

32.

Bagger YZ, Tankó LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33(3):301–307CrossRefPubMed

33.

Hiligsmann M, Reginster JY (2017) The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. Expert Rev Pharmacoecon Outcomes Res 18:1–5. https://doi.org/10.1080/14737167.2017.1375406 CrossRef

34.

Scotti L, Arfe A, Zambon A, Merlino L, Corrao G (2014) Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases. BMJ Open 4(3):e003758. https://doi.org/10.1136/bmjopen-2013-003758 CrossRefPubMedPubMedCentral

35.

Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M (2011) Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ 14(1):99–107. https://doi.org/10.3111/13696998.2010.547967 CrossRefPubMed

36.

Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S (2012) Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone 51(3):324–331. https://doi.org/10.1016/j.bone.2012.05.020 CrossRefPubMed

37.

National Institute for Health and Care Excellence (2017) Bisphosphonates for treating osteoporosis TA464

38.

Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 17(5):637–650. https://doi.org/10.1007/s00198-005-0015-8 CrossRef

39.

Gustavsson A, Jonsson L, McShane R, Boada M, Wimo A, Zbrozek AS (2010) Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease. Int J Geriatr Psychiatry 25(6):622–632. https://doi.org/10.1002/gps.2385 CrossRefPubMed

40.

Eurostat database (2017) http://ec.europa.eu/eurostat/data/database

41.

Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uuskula A, Tosteson ANA, Jonsson B, Kanis JA (2017) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 29:557–566. https://doi.org/10.1007/s00198-017-4317-4 CrossRef

42.

Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112. https://doi.org/10.1007/s00198-003-1516-y CrossRefPubMed

43.

Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473CrossRefPubMed

44.

Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443–446CrossRefPubMed

45.

Poor G, Atkinson EJ, O'Fallon WM, Melton LJ, 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res (319):260-265

46.

Looker AC, Orwoll ES, Johnston JRCC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12(11):1761–1768CrossRefPubMed

47.

Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, Jick S (2012) Persistence with osteoporosis medications among postmenopausal women in the UK general practice research database. Menopause 19(1):33–40CrossRefPubMed

Titel: Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
verfasst von: A. Svedbom
P. Hadji
E. Hernlund
R. Thoren
E. McCloskey
R. Stad
B. Stollenwerk
Publikationsdatum: 03.07.2019
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 9/2019
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05064-w

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

Abstract

Summary

Purpose

Materials and methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Summary

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture

The association between prevalent vertebral fractures and bone quality of the distal radius and distal tibia as measured with HR-pQCT in postmenopausal women with a recent non-vertebral fracture at the Fracture Liaison Service

Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials

Saving bones without risking brain—bisphosphonates and risk of stroke: matched case-control study

Nutritional hypophosphatemic rickets secondary to Neocate® use

Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie